Filter posts

FDA Acts on Biosimilars

The Biologics Price Competition and Innovation Act (BPCIA) deferred to the Food and Drug Administration …

BIO Is Almost Here – What To Consider Before Entering New Therapeutic Areas

Over the past decade, the biopharmaceutical industry has witnessed a shift towards specialty care. From …

New PhRMA report: Nearly 800 Cancer Medicines in Development

A new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) shows that biopharma …

Tekmira Pharmaceuticals Ebola Drug Gets Nod From FDA

The U.S. Food and Drug Administration has authorized Canada’s Tekmira Pharmaceuticals to provide an experimental drug …

Chicago Tribune Makes a Case for GMOs

The editorial board of the Chicago Tribune recently wrote a great piece arguing why this state-by-state …

U.S. Rep. Charlie Dent Discusses PDUFA and NIH Funding at #BIOCEO14

During the 16th Annual BIO CEO & Investor Conference, U.S. Representative Charlie Dent of Pennsylvania, …

National Traceability System Moves into Implementation

Last week, President Obama signed into law the Drug Quality and Security Act (H.R. 3204), …

Legislative Hopes, Fears

Biotechnology advances are poised now more than ever to help policymakers achieve their goals of …

Approving Drugs for Alzheimer’s Disease

BIOtechNOW delves into the current state of Alzheimer’s disease research with today’s feature on regulatory …

Orphan Drugs: Making Rare Diseases Rarer

A panel at the BIO CEO & Investor Conference provided an analysis of the thriving …